CAGED Consortium maps a genomics response to rising infectious threats across Africa and Southeast Asia
The CAGED Consortium brings together six research institutions across Africa and Asia to confront a shared clinical problem: pathogens that are expanding in burden, adapting under selective pressure, and moving through populations with little room for delay in diagnosis or response. The collaboration links the Africa Health Research Institute, the Center for Infectious Disease Research in Africa, the KEMRI-Wellcome Trust Research Programme, the Malawi Liverpool Wellcome Programme, the Mahidol Oxford Tropical Medicine Research Unit, and the Oxford University Clinical Research Unit.
The program centers on four major infectious threats: chikungunya virus, dengue virus, multidrug-resistant Klebsiella pneumoniae, and drug-resistant Mycobacterium tuberculosis. Each of these pathogens carries a distinct clinical burden, but they share one practical feature: control depends on knowing how organisms evolve, where they circulate, and how quickly local systems can detect change. Genomics turns that abstract need into a usable clinical tool. When resistance emerges, transmission accelerates, or a viral lineage shifts, sequencing can identify the change before routine surveillance catches up.
Climate change sits in the background of the consortium’s rationale. It is not presented as a single cause, but as one of the forces shaping the distribution, transmission, and burden of some of these pathogens. For vector-borne infections such as chikungunya and dengue, shifts in temperature, rainfall, and ecological conditions can alter where mosquito vectors thrive and how efficiently they spread disease. In bacterial and mycobacterial infection, environmental and health-system pressures can still change the tempo of spread, especially where antimicrobial resistance and delayed diagnosis intersect.
Pathogens that require local genomic capacity, not distant interpretation
The consortium’s clinical logic is straightforward. Infectious disease threats in Africa and Southeast Asia are not static, and outside laboratories alone cannot provide the speed or local context needed for outbreak preparedness. Sequencing performed far from the point of care may yield scientifically useful data, but it does not automatically strengthen the local systems that must make decisions in real time.
CAGED is designed to narrow that gap. Its stated goals include unraveling the molecular epidemiology of escalating infectious diseases of public health importance and building sustainable local sequencing capacity. In practical terms, that means training, infrastructure, and data systems must be developed alongside pathogen discovery. Without those foundations, genomic surveillance risks becoming episodic rather than durable.
For multidrug-resistant Klebsiella pneumoniae, this matters because resistance profiles can change rapidly under antimicrobial pressure, especially in clinical environments where empiric therapy is common and options are limited. For drug-resistant Mycobacterium tuberculosis, the same principle applies in a slower-moving but no less consequential way. Transmission chains may persist unless molecular epidemiology identifies how strains are moving through communities and healthcare settings. The value of genomics here is not theoretical. It can inform outbreak investigation, resistance tracking, and the design of regionally appropriate control strategies.
For chikungunya and dengue, the challenge is equally clinical but biologically different. Viral population structure, vector ecology, and human movement patterns can all influence when and where outbreaks emerge. Sequencing offers a way to link those patterns to actual circulating strains rather than relying on syndromic impressions alone.
Cross-continent collaboration is the program’s central mechanism
The consortium rests on a simple premise: expertise in one region can strengthen another when the pathogens, transmission dynamics, and public health pressures overlap. Africa and Southeast Asia face different health-system realities, yet both regions contend with infectious diseases that can rise quickly, travel widely, and strain already stretched diagnostic capacity. Cross-continent partnership allows investigators to compare approaches, standardize methods, and build a shared scientific framework around the molecular epidemiology of high-burden infections.
That structure also has a workforce dimension. Sequencing capacity is not built by equipment alone. It depends on trained personnel who can generate data, interpret results, manage samples, and maintain quality over time. Sustainable local sequencing capacity therefore becomes both a scientific and a systems-level intervention. It can support not only outbreak response but also ongoing surveillance, resistance monitoring, and regional research independence.
The paper outlines planned activities and future directions rather than reporting trial results or patient-level outcomes. Even so, the clinical importance is clear. Health systems cannot respond early to emerging outbreaks if the underlying pathogens remain poorly characterized. Molecular epidemiology provides the map; local capacity determines whether anyone can use it fast enough to matter.
Infectious disease preparedness now depends on sequence data as much as bedside observation
One sentence captures the urgency here: pathogens that evolve across borders require surveillance that does the same.
That is the practical consequence of the CAGED model. If genomic data are generated, interpreted, and acted on locally, public health teams gain a chance to detect new transmission patterns before they become larger outbreaks. If that work stays concentrated in a few distant centers, the delay can cost precious time in diseases where speed shapes containment.
The consortium’s focus on escalating infectious diseases is especially relevant because each target pathogen raises a different challenge for clinical care. Dengue and chikungunya can overwhelm outpatient and inpatient services during outbreaks, while resistant Klebsiella pneumoniae and Mycobacterium tuberculosis threaten treatment success through antimicrobial failure and prolonged transmission. A common genomics platform can help distinguish imported cases from local spread, detect resistance signals, and support more precise public health interventions.
The paper also frames CAGED as a response to future emerging infectious disease outbreaks. That forward-looking emphasis is important because pandemic preparedness is no longer confined to high-income settings or to any single pathogen class. Regions with established surveillance, trained sequencing teams, and cross-institutional links are better positioned to respond when a new organism appears or an old one changes behavior.
The limits of the current article are built into its format. It is an outline of goals, activities, and challenges, not an outcomes report. No sequencing yield, outbreak count, enrollment figure, or intervention endpoint is provided. What remains clinically relevant is the framework itself: a multi-institutional genomics consortium built to track resistant bacteria and high-burden viral infections across two regions where timely molecular surveillance can shape future control efforts.